$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of the differences between pemetinib (Dabotan) and first-, second- and third-generation targeted drugs
2026-02-01 22:25:32
Check Details
Erdafitinib (Boke) belongs to which generation of targeted drugs and its differences from similar drugs
2026-02-01 22:25:32
Check Details
When was Erlotinib officially launched in China and its post-marketing applications?
2026-02-01 22:25:32
Check Details
Can tofacitinib (Shangjie) be taken for a long time and recommendations for safe use by patients with chronic diseases
2026-02-01 22:25:32
Check Details
Discussion on whether taking cycloserine for three months will increase the risk of leukemia
2026-02-01 22:25:32
Check Details
What kind of important antibacterial drugs does linezolid (Siwo) belong to and its hierarchical management status?
2026-02-01 22:25:32
Check Details
Patients’ personal experiences after taking Ribociclib (Kaillon) for one year, including efficacy stability and side effects
2026-02-01 22:25:32
Check Details
Analysis of which immune antibody type Cemiplimab, as a PD-1 antibody drug, belongs to
2026-02-01 22:25:32
Check Details
Recommended dosage of daprodustat and individualized dosage adjustment plans for different patient groups
2026-02-01 22:25:32
Check Details
Differences in efficacy and indications between durvalumab (durvalumab) and pembrolizumab
2026-02-01 22:25:32
Check Details
Are zolbetuximab and zolbetuximab the same drug and explanation of naming differences
2026-02-01 22:25:32
Check Details
Does EIKANCE 0.01% Atropine Sulfate Eye Drops require refrigeration and the impact of storage conditions on its efficacy?
2026-02-01 22:25:32
Check Details
1
2
...
2445
2446
2447
2448
2449
2450
2451
...
10214
10215
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
ROS and Cancer: The Potential of Natural Antioxidants
2
LONSURF® (Trifluridine/Tipiracil): Unveiling the Global R&D and Supply Chain Behind the Oral Chemotherapy
3
Breaking the Bottleneck: KOSELUGO® (Selumetinib) Reshapes the Treatment Landscape for Neurofibromatosis Type 1 (NF1)
4
FDA Approves Lilly's Inluriyo (Imlunestrant) for ESR1-Mutant Advanced Breast Cancer
5
Niraparib: A PARP Inhibitor for Ovarian Cancer Maintenance Therapy
6
Abiraterone Acetate: CYP17 Inhibitor for Advanced Prostate Cancer
7
Plerixafor: Mobilizing Hematopoietic Stem Cells for Autologous Transplantation
8
Brensoctib: Managing Side Effects of the Novel DPP-1 Inhibitor for Bronchiectasis
9
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
10
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
11
Trelagliptin: The First Once-Weekly DPP-4 Inhibitor Revolutionizing Type 2 Diabetes Care
12
Adagrasib Medication Management Guide for Special Populations